Baidu
map

J Hepatol:肝脏僵硬测量可检测出晚期肝纤维化,并可预测丙型肝炎相关事件

2018-08-31 MedSci MedSci原创

在初级保健卫生系统管理的CHC,由LSM所确定的晚期纤维化的流行率显著的,且与医院队列的流行率相当。此外,本研究支持将LSM作为CHC人群的社区筛选工具。

研究背景:这项研究旨在确定肝硬度测量(LSM)的流行程度,并评估晚期肝脏疾病和肝脏相关事件的预测因素。

研究方法:该研究纳入澳大利亚维多利亚市初级保健卫生系统中的成年CHC患者。入选标准包括:CHC的存在超过6个月,最近(<18个月)没有给予医治,也没有肝细胞癌病史。在初级保健中进行临床评估、LSM和静脉切开术。为了进行比较,招募了一组医院队列。参与者被纵向跟踪,并对与肝脏有关的事件进行监测。

研究结果:在26个月的时间内,研究共纳入780例社区患者。LSM的中位数值是6.9 kPa,16.5%的患者有晚期肝纤维化的风险(LSM≥12.5 kPa);其中,8.5%的患者无晚期肝病的实验室特征。社区患者 和医院患者的肝硬化风险无显著差异 (p=0.169)。高危饮酒、年龄增长、体重指数升高和丙氨酸氨基转移酶是升高的LSM的独立预测因子。平均随访时间为15.2个月时,与肝脏有关的事件发生在LSM≥12.5 kPa的患者中。LSM为24kPa时,对肝脏相关的事件具有最高的预测能力(危险比率为152;p < 0.001)。

研究结论:在初级保健卫生系统管理的CHC,由LSM所确定的晚期纤维化的流行率显著的,且与医院队列的流行率相当。此外,本研究支持将LSM作为CHC人群的社区筛选工具。

原始出处

Bloom S, Kemp W, Nicoll A, et al. Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis C. J Hepatol, 2018, 69(3), 575-583.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1980760, encodeId=ed9e1980e60a1, content=<a href='/topic/show?id=218f59862cd' target=_blank style='color:#2F92EE;'>#晚期肝纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59862, encryptionId=218f59862cd, topicName=晚期肝纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jul 23 05:26:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808220, encodeId=2c0b180822046, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 30 11:26:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274640, encodeId=d89612e464045, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sun Sep 02 06:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427215, encodeId=b919142e2159f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Sep 02 06:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1980760, encodeId=ed9e1980e60a1, content=<a href='/topic/show?id=218f59862cd' target=_blank style='color:#2F92EE;'>#晚期肝纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59862, encryptionId=218f59862cd, topicName=晚期肝纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jul 23 05:26:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808220, encodeId=2c0b180822046, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 30 11:26:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274640, encodeId=d89612e464045, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sun Sep 02 06:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427215, encodeId=b919142e2159f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Sep 02 06:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1980760, encodeId=ed9e1980e60a1, content=<a href='/topic/show?id=218f59862cd' target=_blank style='color:#2F92EE;'>#晚期肝纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59862, encryptionId=218f59862cd, topicName=晚期肝纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jul 23 05:26:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808220, encodeId=2c0b180822046, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 30 11:26:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274640, encodeId=d89612e464045, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sun Sep 02 06:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427215, encodeId=b919142e2159f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Sep 02 06:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1980760, encodeId=ed9e1980e60a1, content=<a href='/topic/show?id=218f59862cd' target=_blank style='color:#2F92EE;'>#晚期肝纤维化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59862, encryptionId=218f59862cd, topicName=晚期肝纤维化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jul 23 05:26:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808220, encodeId=2c0b180822046, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 30 11:26:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274640, encodeId=d89612e464045, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sun Sep 02 06:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427215, encodeId=b919142e2159f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Sep 02 06:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=)]
    2018-09-02 gwc384

相关资讯

Gut:采用直接抗病毒药物治疗HCV患者,可调节循环脂蛋白和脂质负载能力

采用DAA治疗慢性丙型肝炎患者,可有效根除丙型肝炎病毒和改善肝脏纤维化程度,同时有利于脂蛋白/apo的代谢。

BMC Infect Dis:DAA治疗对临床实践的影响

研究证实基于选择中心网络的干预和根据疾病严重程度对患者进行优先排序是成功的。需要进一步的研究来确定DAAs治疗后的HCV的清除是否能够阻止或甚至逆转非肝硬化患者的肝纤维化程度,或者提高那些达到肝硬化SVR12患者的生活质量和预期寿命。

J Gastroenterol Hepatol:HCV病毒的根除可以逆转胰岛素耐受并改善血糖控制

研究表明,HCV在IR的发展过程中所起的作用,病毒的根除可以逆转IR并改善血糖控制。

J Viral Hepat:Toll样受体4多态性与印度患者感染戊型肝炎病毒的关系

研究首次报道了TLR4多态性与戊型肝炎的关系,并提示HEV感染时TLR4低反应性可能与其多态性有关。

Liver Int:在埃塞俄比亚CHB患者中,HDV感染很少见,但与更严重的肝纤维化相关

研究表明,HDV感染在埃塞俄比亚很少见,但与更严重的肝纤维化相关。

AP&T:肌肉减少症与慢性乙肝的代谢不良受的患者中肝纤维化的风险增加相关

肌肉减少症与肝纤维化程度显着相关。本研究调查了肌肉减少症对慢性乙型肝炎患者肝纤维化的影响。

Baidu
map
Baidu
map
Baidu
map